Contact

Resource Category: Publications

Hydrophilic Linker Architectures in ADCs — Where You Place Polarity Changes What It Does

Potent ADC payloads are often hydrophobic, raising the risk of aggregation, fast clearance and off-target toxicity. Our Journal of Controlled Release review maps hydrophilic linker design by position and shows why placement matters as much as motif.

Boosting mRNA Therapeutics: pHLIP Enhances Endosomal Escape and Gene Expression in Lipid Nanoparticle

Caixia Liu et al. Adv Healthc Mater. 2025.

A chemical biology screen identifies a vulnerability of neuroendocrine cancer cells to SQLE inhibition

Mahoney CE, Pirman D, Crompton JG, et al. A chemical biology screen identifies a vulnerability of neuroendocrine cancer cells to SQLE inhibition. Nat Commun. 2019;10(1):96.

Exploration of a Class of Aryl Imidazolyl Ureas As Potent Acid Ceramidase Inhibitors for the Treatment of Fibrotic Diseases

Beresis R, et al. ACS Omega. 2025 Jul 31;10(31):34747-34761. doi: 10.1021/acsomega.5c03734. eCollection 2025 Aug 12.

mRNAdesigner: an integrated web server for optimizing mRNA design and protein translation in eukaryotes

Ouyang Mo et al. Nucleic Acids Res. 2025 Jul 7;53(W1):W415-W426. doi: 10.1093/nar/gkaf410.

Evaluation of anti-leukemic activity and underlying mechanisms of the novel GSPT1 degrader AB138 in acute myeloid leukemia

Liqiang Wang, Xin Cai, Yongsheng Wang, Yang Kong, Qingchun Wu, Wei Hu, et al. Invest New Drugs. 2025 Jun;43(3):646-655. doi: 10.1007/s10637-025-01541-8. Epub 2025 May 14.

Discovery of ART0380, a Potent and Selective ATR Kinase Inhibitor Undergoing Phase 2 Clinical Studies for the Treatment of Advanced or Metastatic Solid Cancers

Carroll CL, Li M, Wu Q, et al. J Med Chem. 2024 Dec 26;67(24):21890-21904. doi: 10.1021/acs.jmedchem.4c01595. Epub 2024 Dec 4.

iPSC-induced neurons with the V337M MAPT mutation are selectively vulnerable to caspase-mediated cleavage of tau and apoptotic cell death

Theofilas P, et al. Mol Cell Neurosci. 2024 Sep:130:103954.

Ataxia-Telangiectasia Mutated Loss-of-Function Displays Variant and Tissue-Specific Differences across Tumor Types

Pilié PG, Hung Le et al. Clin Cancer Res. 2024 May 15;30(10):2121-2139. doi: 10.1158/1078-0432.CCR-23-1763.

Identification of tau-tubulin kinase 1 inhibitors by microfluidics-based mobility shift assay from a kinase inhibitor library

Jinlei Wang, et al. SLAS Discov. 2023 Dec;28(8):385-393. doi: 10.1016/j.slasd.2023.06.003. Epub 2023 Jul 1.
START YOUR JOURNEY
Phase
Modality
Therapeutic Area